<DOC>
	<DOCNO>NCT02065609</DOCNO>
	<brief_summary>The main purpose study see Positron Emission Tomography ( PET-Imaging ) 89Zr label trastuzumab detect trastuzumab ( HER2 ) positive breast cancer .</brief_summary>
	<brief_title>89ZrTrastuzumab Breast Imaging With Positron Emission Tomography</brief_title>
	<detailed_description />
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Female patient 18 year age old Cohort 1 : Her2positive ( define 3+ ) FISH HER2 : CEP17 ratio &gt; 2 biopsy prove breast cancer Cohort 2 : Her2positive ( define 3+ ) FISH HER2 : CEP17 ratio &gt; 2 OR HER2negative ( 0 1+ , 2+ FISH negative ) biopsyproven breast cancer Primary recurrent/metastatic lesion size â‰¥ 1.5 cm determine image study ( ultrasonography , mammography , CT MRI ) physical examination Able give inform consent Not currently pregnant nursing : Subject must surgically sterile ( documented bilateral oophorectomy and/or document hysterectomy ) , postmenopausal ( cessation menses 1 year ) , nonlactating , childbearing potential urine pregnancy test ( test perform within 24 hour period immediately prior administration 89Zrtrastuzumab ) negative Patients currently receive trastuzumab therapy without type systemic therapy participate disease progress ( development new lesion ( ) worsen know lesion ( ) base image modality physical examination . Patients invasive malignancy , exception non melanoma skin cancer , ( ) evidence cancer present within last 5 year Unable tolerate 60 min PET image per image session</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Trastuzumab</keyword>
</DOC>